ReviewCurrent gastroenterology reports2020
Refractory Celiac Disease.
Review in Current gastroenterology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Celiac Disease Is Associated with Microscopic Colitis in Refractory Cases in Adults: A Systematic Review and Meta-Analysis of Observational Studies.Digestive diseases and sciences · 2022Pooled it
- From gluten to therapeutics: molecular mechanisms of celiac disease and emerging alternatives to the gluten-free diet.Frontiers in pharmacology · 2026Review
- Malignancies in Celiac Disease-A Hidden Threat with Diagnostic Pitfalls.Biomedicines · 2025Review
- Clinical settings in which human leukocyte antigen typing is still useful in the diagnosis of celiac disease.World journal of gastroenterology · 2025Review
- Celiac Disease: Beyond Diet and Food Awareness.Foods (Basel, Switzerland) · 2025Review
- Celiac Disease, Gluten Sensitivity, and Diet Management.Current gastroenterology reports · 2024Review
- Cross-sectional imaging: current status and future potential in adult celiac disease.European radiology · 2024Review
- Advanced enteropathy-associated T cell lymphoma (EATL) presenting with severe malabsorption and concomitantly diagnosed coeliac disease (CD).BMJ case reports · 2023Article
- Old and New Adjunctive Therapies in Celiac Disease and Refractory Celiac Disease: A Review.International journal of molecular sciences · 2023Review
- Intestinal Enteroendocrine Cells: Present and Future Druggable Targets.International journal of molecular sciences · 2023Review
- Smad7 as a positive regulator of intestinal inflammatory diseases.Current research in immunology · 2023Review
- Refractory celiac disease and its mimickers: a review on pathogenesis, clinical-pathological features and therapeutic challenges.Frontiers in oncology · 2023Review
- Extranodal T- and NK-cell lymphomas.Virchows Archiv : an international journal of pathology · 2023Review
- Celiac Disease in the Elderly.Current treatment options in gastroenterology · 2022Article
- Artificial Intelligence Analysis of Celiac Disease Using an Autoimmune Discovery Transcriptomic Panel Highlighted Pathogenic Genes including BTLA.Healthcare (Basel, Switzerland) · 2022Article
- Vaccination Status and Attitudes towards Vaccines in a Cohort of Patients with Celiac Disease.Vaccines · 2022Article
- Spontaneous Latency in Adult Patients with Celiac Disease on a Normal Diet after Gluten-Free Diet: Case Series.Middle East journal of digestive diseases · 2022Article
- Possible relationship between refractory celiac disease and malignancies.World journal of clinical oncology · 2022Review
- Iron Deficiency in Celiac Disease: Prevalence, Health Impact, and Clinical Management.Nutrients · 2021Review
- Persistent Skin Symptoms after Diagnosis and on a Long-term Gluten-free Diet in Dermatitis Herpetiformis.Acta dermato-venereologica · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewTo review the epidemiology, pathophysiology, diagnosis, management, and prognosis of refractory celiac disease, with a specific emphasis on recent literature. RECENT
findingsWhile the pathophysiology of type I refractory celiac disease remains unclear, there have been advances in the understanding of the pathophysiology of type II refractory celiac disease. This has included recognition of the significant role of interleukin-15 and somatic mutations in JAK1 or STAT3 in the proliferation of aberrant T cells. This in turn has led to potential novel therapies targeting these factors, one of which has reached the clinical trial stage. The morbidity and mortality associated with type II refractory celiac disease remain significant; however, recent advances in the understanding of the pathophysiology of this condition have led to potential therapeutic options that should be investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.